SLC5A2 and type 2 diabetes mellitus: This study aims to elucidate mechanisms underlying SGLT2’s selective inhibitor EMPA, which improves the lipid deposition within the kidney of T2DM patients, a high-AGEs diet-fed T2DM mouse model, as well as AGEs-exposed HK-2 cells.